The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barillé, S.
Right arrow Articles by Amiot, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barillé, S.
Right arrow Articles by Amiot, M.
The Journal of Immunology, 1999, 163: 5723-5728.
Copyright © 1999 by The American Association of Immunologists

Production of Metalloproteinase-7 (Matrilysin) by Human Myeloma Cells and Its Potential Involvement in Metalloproteinase-2 Activation1

Sophie Barillé2,*, Régis Bataille*, Marie-José Rapp{dagger}, Jean-Luc Harousseau*,{dagger} and Martine Amiot*

* Institut National de la Santé et de la Recherche Médicale U463, Institut de Biologie, Nantes, France; and {dagger} Hématologie clinique, Hôtel-Dieu, Nantes, France

Matrix metalloproteinases (MMPs) play a critical role in bone remodeling and tumor spreading. Multiple myeloma (MM) is a plasma cell malignancy primarily localized within the bone marrow and characterized by its capacity to destroy bone matrix and to disseminate. We have reported recently that human myeloma cells were able to induce the conversion of pro-MMP-2 produced by the tumoral environment in its activated form. In the current study, we have investigated the mechanism involved in this process. We demonstrate that a soluble MMP constitutively produced by myeloma cells was responsible for pro-MMP-2 activation. Furthermore, we show that the soluble MMP, MMP-7, also known as matrilysin, was able to activate the MMP-2 produced in its latent form by bone marrow stromal cells. Finally, we demonstrate that myeloma cells constitutively produce MMP-7 with expected proteolytic activity. Our results suggest that MMP-7 produced by myeloma cells could participate in bone destruction and tumor spreading in MM, on one hand by its own proteolytic activity and on the other hand by its capacity to activate pro-MMP-2. These findings strengthen the idea that inhibition of MMP activity could represent an interesting therapeutic approach in MM.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Romagnoli, G. Desplanques, S. Maiga, S. Legouill, M. Dreano, R. Bataille, and S. Barille-Nion
Canonical Nuclear Factor {kappa}B Pathway Inhibition Blocks Myeloma Cell Growth and Induces Apoptosis in Strong Synergy with TRAIL
Clin. Cancer Res., October 15, 2007; 13(20): 6010 - 6018.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Zhang, X. Jin, S. Fang, R. Wang, Y. Li, N. Wang, W. Guo, Y. Wang, D. Wen, L. Wei, et al.
The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma
Carcinogenesis, October 1, 2005; 26(10): 1748 - 1753.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
E. Godefroy, A. Moreau-Aubry, E. Diez, B. Dreno, F. Jotereau, and Y. Guilloux
{alpha}v{beta}3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen
J. Exp. Med., July 5, 2005; 202(1): 61 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Van Valckenborgh, P. I. Croucher, H. De Raeve, C. Carron, E. De Leenheer, S. Blacher, L. Devy, A. Noel, E. De Bruyne, K. Asosingh, et al.
Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma: A Study in the 5T2MM Mouse Model
Am. J. Pathol., September 1, 2004; 165(3): 869 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z.-S. Zeng, W.-P. Shu, A. M. Cohen, and J. G. Guillem
Matrix Metalloproteinase-7 Expression in Colorectal Cancer Liver Metastases: Evidence for Involvement of MMP-7 Activation in Human Cancer Metastases
Clin. Cancer Res., January 1, 2002; 8(1): 144 - 148.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology, January 1, 2002; 2002(1): 214 - 240.
[Abstract] [Full Text]

Home page
 BloodHome page
N. Giuliani, R. Bataille, C. Mancini, M. Lazzaretti, and S. Barille
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
Blood, December 15, 2001; 98(13): 3527 - 3533.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
N. Di Girolamo, M. T. Coroneo, and D. Wakefield
Active Matrilysin (MMP-7) in Human Pterygia: Potential Role in Angiogenesis
Invest. Ophthalmol. Vis. Sci., August 1, 2001; 42(9): 1963 - 1968.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. D. Roodman
Biology of Osteoclast Activation in Cancer
J. Clin. Oncol., August 1, 2001; 19(15): 3562 - 3571.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Ozaki, T. Mizuta, G. Zhao, H. Yotsumoto, T. Hara, S. Kajihara, A. Hisatomi, T. Sakai, and K. Yamamoto
Involvement of the Ets-1 Gene in Overexpression of Matrilysin in Human Hepatocellular Carcinoma
Cancer Res., November 1, 2000; 60(22): 6519 - 6525.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.